• Century Therapeutics presented new preclinical CNTY-813 data at the ADA 2026 meeting, positioning the program toward a first-in-human study.
• Studies showed sustained blood-sugar control with no signs of abnormal cell growth, supporting the therapy’s functional performance and safety profile.
• Immune-evasion engineering helped the transplanted cells keep working under immune attack in animal models, pointing to reduced need for immunosuppression.
• A Phase 1 manufacturing process was established, a key step for trial supply and potential scale-up.
• IND filing remains targeted for 4Q 2026; initial clinical readouts are expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606081605PRIMZONEFULLFEED9733527) on June 08, 2026, and is solely responsible for the information contained therein.